A Verdict for Glimepiride: Effective and Not Guilty of Cardiovascular Harm.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

9 citing papers in PubMed.

1. Comparative study of Dapagliflozin versus Glimepiride effect on insulin regulated aminopeptidase (IRAP) and interleukin-34 (IL-34) in patient with type 2 diabetes mellitus.Scientific reports · 2023
   Trial
2. Cardiovascular outcomes and safety with linagliptin, a dipeptidyl peptidase-4 inhibitor, compared with the sulphonylurea glimepiride in older people with type 2 diabetes: A subgroup analysis of the randomized CAROLINA trial.Diabetes, obesity & metabolism · 2021
   Trial
3. Repositioning Tradition: A Narrative Review and Expert Opinion on the Clinical Positioning of Glimepiride and Metformin in Nepal's Type 2 Diabetes Mellitus (T2DM) Landscape.Cureus · 2026
   Review
4. Drug utilization pattern among type II diabetic patients in Palestine.BMC health services research · 2025
   Article
5. The Enhanced Cardiac Outcome of Conjugated SGLT2 Inhibitors and GLP-1RA Therapy in Diabetic Patients.Current cardiology reports · 2022
   Review
6. Efficacy and Safety of Ertugliflozin in Patients With Diabetes Mellitus Inadequately Controlled by Sulfonylurea Monotherapy: a Substudy of VERTIS CV.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2021
   Article
7. Effect of linagliptin, a dipeptidyl peptidase-4 inhibitor, compared with the sulfonylurea glimepiride on cardiovascular outcomes in Asians with type 2 diabetes: subgroup analysis of the randomized CAROLINA® trial.Diabetology international · 2021
   Article
8. Glimepiride and Metformin Combinations in Diabetes Comorbidities and Complications: Real-World Evidence.Cureus · 2020
   Article
9. Report from the 5th cardiovascular outcome trial (CVOT) summit.Cardiovascular diabetology · 2020
   Article

Corrections and comments

• Commented on by
  Using Real-World Data to Predict Findings of an Ongoing Phase IV Cardiovascular Outcome Trial: Cardiovascular Safety of Linagliptin Versus Glimepiride.2019

Authors and funding

1 author.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as